Cardiff Oncology, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
CRDF$0.79-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(38,635) | $(33,644) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 276 | 308 |
| Stock-based compensation expense | 4,432 | 3,556 |
| Amortization of right-of-use assets | 405 | 404 |
| Accretion of discounts on short-term investments, net | (690) | (440) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable and unbilled receivable | 519 | (330) |
| Prepaid expenses and other current assets | 1,468 | 1,084 |
| Other assets | (480) | 12 |
| Accounts payable and accrued liabilities | 1,262 | 2,087 |
| Operating lease liabilities | (513) | (463) |
| Net cash used in operating activities | (31,956) | (27,426) |
| Investing activities | ||
| Capital expenditures | (44) | (80) |
| Maturities of short-term investments | 54,539 | 22,595 |
| Purchases of short-term investments | (65,138) | (23,563) |
| Sales of short-term investments | 1,236 | 10,265 |
| Net cash provided by (used in) investing activities | (9,407) | 9,217 |
| Financing activities | ||
| Proceeds from sales of common stock, net of expenses of $0 and $482, respectively | — | 9,232 |
| Proceeds from exercise of options | 28 | 360 |
| Net cash provided by financing activities | 28 | 9,592 |
| Net change in cash and cash equivalents | (41,335) | (8,617) |
| Cash and cash equivalents—Beginning of period | 51,470 | 21,655 |
| Cash and cash equivalents—End of period | $10,135 | $13,038 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.